2022
NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
Marks A, Antaya R, Balsamo L, Cardinale K, Cheron R, Frumberg D, Gentile V, Habib L, Puthenpura V, Zhang H. NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies. Neuro-Oncology 2022, 24: i129-i129. PMCID: PMC9165028, DOI: 10.1093/neuonc/noac079.469.Peer-Reviewed Original ResearchTuberous sclerosisPediatric patients 2 yearsYale-New Haven Children's HospitalInoperable plexiform neurofibromasPatients 2 yearsOwn side effectsYears of ageNeurofibromatosis type 1Multidisciplinary clinicNeurocutaneous syndromeChildren's HospitalPlexiform neurofibromaNeuro-oncologySide effectsSubspecialty consultationClinicType 1Young adultsSclerosisSyndromeHospitalTherapyAgeTreatmentClinical reasoning
2015
Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331
Mitchell H, Lu X, Myers RM, Sung L, Balsamo LM, Carroll WL, Raetz E, Loh ML, Mattano LA, Winick NJ, Devidas M, Hunger SP, Maloney K, Kadan-Lottick N. Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. International Journal Of Cancer 2015, 138: 332-339. PMID: 26235006, PMCID: PMC5138856, DOI: 10.1002/ijc.29708.Peer-Reviewed Original ResearchConceptsStandard-risk acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaLife Inventory 4.0 Generic Core ScalesChildren's Oncology Group studyHRQoL 1 monthMean PedsQL scoresYears of therapyHealth-related qualityEnd of inductionHigh cure ratesGeneric Core ScalesSocial functioningRepeated-measures analysisTherapy completionTherapeutic trialsCure ratePediatric QualityPedsQL scoresConsiderable impairmentLongitudinal assessmentDiagnosisTherapyMonthsGroup study